Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
HIV clinic's hardest battle in treating people is helping them to overcome the social stigma

Jason, who is using a pseudonym, is a heterosexual black man of African heritage. He is typical of the patients seen at the clinic in University Hospital Lewisham. There are 850 patients on the books, more than 50 per cent are heterosexual and most of African origin. Many live on the poverty line and struggle with mental health problems. But the biggest challenge facing the team is the issue of stigma.

Published
10 December 2018
From
Evening Standard
All people with HIV-2 should receive HIV treatment – without it, most will progress to AIDS and death

Most people with HIV-2 infection will progress to AIDS and death unless they receive antiretroviral therapy (ART), according to the results of a study conducted in Guinea-Bissau and

Published
27 November 2018
By
Michael Carter
Early HIV treatment reduces the risk of liver fibrosis

Early antiretroviral therapy (ART) reduces the risk of liver fibrosis progression in people living with HIV, including in people who do not have co-infection with viral hepatitis,

Published
08 November 2018
By
Michael Carter
Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA in Treatment-Naïve Adults with HIV-1

New Phase 3 AMBER study data continues to demonstrate high rates of virologic suppression at 96 weeks in ART-naïve adults with HIV-1 when treated with SYMTUZA

Published
01 November 2018
From
Janssen press release
Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Biktarvy Showed High Efficacy and High Barrier to Resistance Through 96 Weeks

Published
01 November 2018
From
Gilead press release
Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

Dolutegravir-based treatment was no more effective than treatment based on a 400mg dose of efavirenz, a randomised trial conducted in Cameroon has found. However, almost half

Published
01 November 2018
By
Keith Alcorn
Bictegravir matches dolutegravir in first-line treatment

A triple combination containing the new integrase inhibitor bictegravir proved just as effective as a dolutegravir-based combination in suppressing viral load over 96 weeks, but people taking bictegravir

Published
31 October 2018
By
Keith Alcorn
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects

Antiretroviral treatment with a boosted protease inhibitor and one other drug is just as effective as three-drug antiretroviral therapy containing a boosted protease inhibitor but results in

Published
30 October 2018
By
Keith Alcorn
Studies confirm long-term effectiveness of new single-tablet regimens

The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at IDWeek 2018

Published
18 October 2018
By
Liz Highleyman
Rapid Initiation of HIV Care: Assessing Safety and Efficacy

Discussion with Gregory Huhn, MD

Published
16 October 2018
From
Infectious Disease Advisor
← First12345...80Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.